Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 6Melanoma 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma 2Drug-Related Side Effects and Adverse Reactions 2Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 58Nivolumab 37aldesleukin 16Cyclophosphamide 15atezolizumab 12Specimen Handling 11Radiosurgery 10Paclitaxel 10Magnetic Resonance Spectroscopy 10Ipilimumab 9Interleukin-2 9fludarabine 8fludarabine phosphate 7Docetaxel 7Carboplatin 7avelumab 6Radiotherapy 6durvalumab 5Peripheral Blood Stem Cell Transplantation 5Immune Checkpoint Inhibitors 5Cisplatin 5Bevacizumab 5tislelizumab 4temsirolimus 4spartalizumab 4Sirolimus 4Pemetrexed 4Oxaliplatin 4Leucovorin 4Cryosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × denileukin diftitox × Dermatologic × Clear all
NCT00082914 2013-06-20

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡